Q-Line Biotech Ltd
Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]
- Market Cap ₹ 952 Cr.
- Current Price ₹ 408
- High / Low ₹ 735 / 396
- Stock P/E 16.9
- Book Value ₹ 207
- Dividend Yield 0.00 %
- ROCE 23.2 %
- ROE 26.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 313 | 341 | 350 | |
| Sales growth | +9% | -3% | |
| 241 | 242 | 246 | |
| Operating Profit | 72 | 99 | 103 |
| OPM % | 23% | 29% | 30% |
| 17 | 5 | 6 | |
| Interest | 15 | 19 | 20 |
| Depreciation | 7 | 11 | 15 |
| Profit before tax | 67 | 74 | 74 |
| Tax % | 29% | 23% | |
| 47 | 57 | 56 | |
| EPS in Rs | 27.76 | 33.35 | 29.41 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|
| Equity Capital | 2 | 16 | 23 |
| Reserves | 188 | 231 | 460 |
| 160 | 213 | 120 | |
| 99 | 87 | 76 | |
| Total Liabilities | 449 | 547 | 680 |
| 91 | 158 | 141 | |
| CWIP | 59 | 15 | 16 |
| Investments | 0 | 0 | 18 |
| 298 | 374 | 505 | |
| Total Assets | 449 | 547 | 680 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 22 | 21 | |
| -75 | -29 | |
| 46 | 36 | |
| Net Cash Flow | -7 | 28 |
| Free Cash Flow | -48 | -14 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 42% | 47% |
Ratios
Standalone / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 97 | 136 |
| Inventory Days | 225 | 258 |
| Days Payable | 139 | 142 |
| Cash Conversion Cycle | 183 | 252 |
| Working Capital Days | 52 | 65 |
| ROCE % | 23% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2026 | |
|---|---|---|---|---|
| Capacity Utilization - Clinical Chemistry/Rapid/Elisa Kits (Unit 3) % |
|
|||
| Geographic Revenue Mix - North India % |
||||
| Instrument Revenue Share % |
||||
| Number of Customers Served count |
||||
| Number of Distributors count |
||||
| Reagent Revenue Share % |
||||
| Capacity Utilization - Selectra Pro M Analyzers (Unit 2) % |
||||
| Manufacturing Capacity - Selectra Pro M Analyzers (Unit 2) units per year |
||||
| Installed Base - Selectra Pro M Analyzers count |
||||
| Product Licences Granted count |
||||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Q-Line Biotech submits transcript of H1 FY27 earnings call held Nov 13, 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Audio recording of 13 Nov 2026 earnings call for H1 FY2026-27 now available on website.
-
Updates
- Audio recording of earnings call for H1 FY2026-27 unaudited results made available on website.
-
Investor Presentation
- Q-Line Biotech released H1 FY27 investor presentation: revenue Rs152 crore, EBITDA Rs40 crore, PAT Rs20 crore.
-
Monitoring Agency Report
- CARE report notes Rs0.97 crore prepayment charges paid from IPO proceeds; company will restore amount.
Concalls
-
Nov 2026Transcript REC
-
Nov 2026PPT REC
-
Jun 2026Transcript PPT
Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.